Proud to join global leaders in Alzheimer’s clinical research and learn about the newest breakthroughs in biomarkers, diagnostics, and therapeutic strategies.

The discussions on early detection, digital biomarkers, and next-generation clinical trial design were especially inspiring.

At FY BIO, we remain committed to supporting neuroscience and CNS research with high-performance QC reagents, functional assays, and reliable lab consumables.

Looking forward to building more connections and exploring collaboration opportunities in 2025.
#CTAD2025 #Alzheimers #Neuroscience #ClinicalTrials #FYBIO